Concepedia

Z. Mark

ZM

11

Publications

1.9K

Citations

10

H-Index

2009

Active since

Affiliations

University of Maryland, Baltimore(Current)

Hôpital Intercommunal de Créteil

Heidelberg University

University of Maryland, College Park

Samsung Medical Center

Z. Mark is an author at University of Maryland, Baltimore specializing in medicine, lung cancer, and cancer therapeutics.

Top concepts

Publications per year

2009–2019

11

Publications

11

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 568 citations · Full text

, , +5

A Randomized, Double-blind, Placebo-controlled Study of Tumor Necrosis Factor-α Blockade in Severe Persistent Asthma

Sally E. Wenzel, Peter J. Barnes, Eugene R. Bleecker et al. · American Journal of Respiratory and Critical Care Medicine · 2009 · 457 citations

Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer

Jean‐Charles Soria, Z. Mark, Petr Zatloukal et al. · Journal of Clinical Oncology · 2011 · 243 citations · Full text

Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC: Primary and Correlative Biomarker Analyses

Taofeek K. Owonikoko, Huifeng Niu, Kristiaan Nackaerts et al. · Journal of Thoracic Oncology · 2019 · 141 citations · Full text

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

Martin Schüler, James Chih‐Hsin Yang, K. Park et al. · Annals of Oncology · 2015 · 131 citations · Full text

Rows per page

1–5 of 11